Immunome ends BMS milestone and royalty obligations for $20.0 million and 4.4 million shares
Immunome agreed on October 2, 2026 to amend its license agreement with Bristol-Myers Squibb, removing all milestone and royalty payment obligations and transferring certain patent rights for varegacestat and AL101 to the company. The company paid $20.0 million in cash and issued 4,425,487 shares of common stock to BMS, and it agreed to register those shares for resale, which could add supply to the market.
Key points
- Amendment No. 4 dated October 2, 2026 removes all milestone and royalty payments owed to BMS under the license agreement.
- Consideration was $20.0 million in cash plus 4,425,487 newly issued common shares.
- The company agreed to file a resale registration statement for the shares by November 16, 2026.
- The shares were issued under the Section 4(a)(2) private placement exemption and are not registered under the Securities Act.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.